Clinical features and prognostic factors of combined small cell lung cancer: development and validation of a nomogram based on the SEER database

Liu, Yang; Zhou, Yuwen; Wang, Gang; Liú, Dan; Chen, Bojiang; Pu, Dan; Correale, Pierpaolo; Rades, Dirk; Tomita, Yusuke; Inno, Alessandro; Santarpía, Mariacarmela; Li, Yalun; Liu, Weimin

doi:10.21037/tlcr-21-804

Cited by 12 publications

(12 citation statements)

References 27 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SCLC remains a very aggressive and lethal malignant disease. The core treatment for SCLC is chemotherapy in combination with anti-PD-L1 antibodies, for which EP/EC plus Atezolizumab/Durvalumab, particularly for LA-SCLC and ED-SCLC, is most used and significantly improved prognosis (7,22,(25)(26)(27)(28)(29). The efficacy of surgery combined with chemotherapy for LA-SCLC remains controversial (10).…”

Section: Discussionmentioning

confidence: 99%

Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis

Bian¹,

Jiang²,

Xiong³

et al. 2022

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background: The efficacy of surgery in combination of chemotherapy for stage IIIA small cell lung cancer (IIIA-SCLC) is controversial. The aim of the present study was to analyze the efficacy of surgery combined with chemotherapy, especially in the setting of neoadjuvant chemotherapy (NAC) followed by surgery for IIIA-SCLC.Methods: Between 2004 and 2015, we reviewed 2,199 chemotherapy-treated stage IIIA (N1/2) SCLC cases in the Surveillance, Epidemiology, and End Results (SEER) database, and 32 NAC + intentional radical resectiontreated, centrally-located IIIA-SCLC cases at Shanghai Pulmonary Hospital (SPH). Outcomes were compared between surgically and non-surgically treated patients from the SEER database after propensity score matching (PSM), and comparing lobectomy/bi-lobectomy and pneumonectomy patients from SPH. Prognostic factors were evaluated by Kaplan-Meier method and the Cox proportional hazards regression model.Results: There was significantly higher overall survival (OS) in surgically treated IIIA-SCLC patients (OS, 44.8 vs. 21.2 months, P=0.048), and similar efficacy was observed between sub-lobectomy and lobectomy/ bi-lobectomy patients (OS: 55.6 vs. 30.3 months, P=0.167) in SEER database. At SPH, significantly higher OS was associated with T1 stage (before NAC: T1 vs. T2-4, 48.7 vs. 32.2 months, P=0.025; after NAC: T1 vs. T2-4, 42.7 vs. 21.3 months, P=0.048). Female sex [hazard ratio (HR): 0.078, P=0.009], T1 stage (HR: 13.048, P=0.026), and pneumonectomy (HR: 0.095, P=0.009) were independent prognostic factors for IIIA-SCLC patients who received NAC + intentional radical resection.Conclusions: For stage IIIA SCLC patients, complete resection combined with chemotherapy might improve the prognosis than patients without surgery. Post-NAC lobectomy was not found to be superior to sub-lobectomy, while pneumonectomy was considered suitable for central-type IIIA-SCLC patients after NAC treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis

Bian¹,

Jiang²,

Xiong³

et al. 2022

Transl Lung Cancer Res

View full text Add to dashboard Cite

show abstract

“…The SEER database is currently the largest database of tumor clinical information in the world, which can help reduce the cancer burden among the US population. Many significant problems in clinical practice have been published using the SEER database in recent years (19,20). However, the SEER database covers a long period and contains multiple different editions of the AJCC tumor staging system and other indicators, so it was so challenging to compare the results of the delivered research using the SEER database (21).…”

Section: Discussionmentioning

confidence: 99%

The role of surgery in older patients with T1-2N0M0 small cell lung cancer: A propensity score matching analysis

et al. 2022

View full text Add to dashboard Cite

BackgroundSurgical resection could improve the survival of patients with early-stage small cell lung cancer (SCLC). However, there is a lack of dedicated studies concentrating on surgical treatment in older patients with T1-2N0M0 SCLC. Thus, we performed this population-based study to investigate whether older patients with T1-2N0M0 SCLC could benefit from surgery.MethodsWe collected the data of patients with SCLC between 2000 and 2015 from the Surveillance, Epidemiology, and End Results Program database. Older patients (≥ 65 years) with T1-2N0M0 SCLC were included, and we converted the staging information into those of the eighth edition. The propensity score matching (PSM) was used to balance the distribution of clinical characteristics between surgery and no-surgery groups.ResultsBefore PSM, the distribution proportions of clinical characteristics in 1,229 patients were unbalanced. The Kaplan–Meier curves of overall survival (OS) and cancer-specific survival (CSS) showed that the patients in the surgery group were better than those in the non-surgery group (all P < 0.001). After 1:2 PSM, the distribution proportions of clinical characteristics in 683 patients were balanced (all P > 0.05). The OS and CSS of patients in the surgery group were still better than that of patients in the no-surgery group (all P < 0.001), and subgroup analysis showed that the surgery was a protective factor for OS and CSS in all clinical characteristics subgroups (almost P < 0.001). The multivariate Cox analysis further confirmed this result (OS: HR, 0.33; 95% CI, 0.27–0.39; P < 0.001; CSS: HR, 0.29; 95% CI, 0.23–0.36; P < 0.001). The result of subgroup analysis based on age, T stage, and adjuvant therapy showed that surgery was related to better OS and CSS compared with non-surgery group (almost P < 0.001) and that lobectomy exhibited the longer survival than sublobectomy. Age, sex, and race were the independent prognostic factors for OS in patients undergoing surgery, whereas only the factor of age affects the CSS in patients with surgery.ConclusionsOlder patients with T1-2N0M0 SCLC can benefit significantly from surgical treatment, and lobectomy provides better prognosis than sublobectomy.

show abstract

“…The SEER database is an authoritative source of cancer statistics 20 . The baseline information and follow‐up data of all patients involved in this study were obtained from the SEER database (http://seer.cancer.gov/SEERstat) using the SEER*Stat software (version 8.3.9).…”

Section: Methodsmentioning

confidence: 99%

“…The SEER database is an authoritative source of cancer statistics. 20 The baseline information and follow-up data of all patients involved in this study were obtained from the SEER database (http://seer.cancer.gov/SEERstat) using the SEER*Stat software (version 8.3.9). Patients diagnosed with NPC between 2004 and 2015 were selected according to the following inclusion criteria: (1) patients who were diagnosed with NPC by pathology;…”

Section: Data Sourcesmentioning

confidence: 99%

Development and validation of prognostic nomograms in patients with ascending type of nasopharyngeal carcinoma: Retrospective study based on SEER database

et al. 2022

View full text Add to dashboard Cite

Background Nomograms specifically used to predict the prognosis of ascending type nasopharyngeal carcinoma (NPC) have not been constructed. Methods Data of ascending type (T3‐4N0‐1M0) NPC from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2015 were extracted. Results Altogether 862 patients with ascending type NPC were enrolled, including 603 in training cohort and 259 in validation cohort. Age, marital status, pathology, grade, tumor size, T classification, and chemotherapy were the independent prognostic factors for overall survival (OS). Age, marital status, pathology, grade, and chemotherapy were the independent prognostic factors for cancer‐specific survival (CSS). In training cohort, the concordance index of the OS and CSS nomograms were 0.694 (95% confidence interval [CI], 0.677–0.711) and 0.678 (95%CI, 0.659–0.697), respectively, while those in validation cohort were 0.740 (95%CI, 0.715–0.765) and 0.708 (95%CI, 0.679–0.737), separately. Conclusion The as‐constructed nomograms for ascending type NPC could provide accurate prognostic predictions of OS and CSS.

show abstract

Clinical features and prognostic factors of combined small cell lung cancer: development and validation of a nomogram based on the SEER database

Cited by 12 publications

References 27 publications

Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis

Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis

The role of surgery in older patients with T1-2N0M0 small cell lung cancer: A propensity score matching analysis

Development and validation of prognostic nomograms in patients with ascending type of nasopharyngeal carcinoma: Retrospective study based on SEER database

Contact Info

Product

Resources

About